Jiangsu Vcare Approved to Establish "Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center"
Published Time:
2024-11-01 17:51
Source:
Recently, the Nanjing Municipal Science and Technology Bureau announced the acceptance results of 2024 provincial-level engineering research centers and academician workstations. The"Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center", established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), successfully passed project acceptance.
Provincial Engineering Research Centers are key components of Jiangsu's innovation system and vital forces driving high-quality industrial development. Their mission is to promote technological innovation in Jiangsu by strengthening engineering R&D platforms, conducting R&D and technical services, developing common/key technologies, and providing mature technical processes, equipment, and products to facilitate achievement transformation and technological radiation.
During its establishment, the Center built a comprehensive integrated drug R&D platform covering drug discovery, synthesis, analysis, formulation, pharmacological screening, and clinical research. Leveraging this platform, it achieved notable outcomes including Vicagrel, VC004, and VC005—innovative drugs oriented to meeting clinical needs through differentiated solutions, now entering confirmatory clinical stages.
The Center has also cultivated professionals in drug design and clinical development, forming a high-caliber R&D team that enhances the company’s innovation and competitiveness. It will continue deepening R&D efforts to advance China’s pharmaceutical innovation.
Related News
11
2026
/
06
Recently, VC005 topical gel, a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), has officially obtained the IND approval from the CDE for the topical treatment of plaque psoriasis.
View Details
09
2026
/
06
9 June 2026 – Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech，Company), a commercial-stage innovative biopharmaceutical firm leveraging AI for differentiated original drug design, today announced the signing of an exclusive licensing agreement with Everest Medicines (HKEX: 1952.HK). Under the deal, Vcare PharmaTech grants Everest Medicines exclusive rights for the clinical development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across multiple Asia-Pacific countries and regions (including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR and Taiwan region of China).
View Details
04
2026
/
06
On June 4, the official website of the NMPA announced that Vcare PharmaTech’s Class 1 new drug, Eratrectinib (VELMARTO®), has been approved for marketing in China. It is indicated for adult and adolescent patients with advanced solid tumors harboring NTRK gene fusions.
View Details
02
2026
/
06
Capital Empowers Innovation: Vcare PharmaTech Completes Nearly RMB 200 Million Series C3 Financing
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) has successfully closed its Series C3 financing totaling nearly RMB 200 million. The round was led by existing shareholder Hongcheng Investment, with follow-on investments from institutions including Xinghe Venture Capital, Hangzhou Jinlong, Hongyao Kechuang and Huadian Investment. Meanwhile, the firm has onboarded high-caliber new investors such as Huafuruixing, consolidating a solid capital foundation for its sustainable long-term growth.
View Details
12
2026
/
05
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced that VC005 Topical Gel, its self-developed second-generation highly selective JAK1 inhibitor, has completed the enrollment of the first patient in the phase III clinical trial for the treatment of mild-to-moderate atopic dermatitis (AD).
View Details
07
2026
/
05
Recently, VC005 Topical Gel, a second-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), has officially obtained the IND approval from the CDE of the NMPA. The product is intended for the topical treatment of non-segmental vitiligo.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn